Artia Global Partners LP Buys 309,098 Shares of NewAmsterdam Pharma Company N.V. $NAMS

Artia Global Partners LP lifted its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 158.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 503,936 shares of the company’s stock after purchasing an additional 309,098 shares during the period. NewAmsterdam Pharma accounts for 2.4% of Artia Global Partners LP’s holdings, making the stock its 11th biggest position. Artia Global Partners LP’s holdings in NewAmsterdam Pharma were worth $17,678,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Wells Fargo & Company MN grew its stake in shares of NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after acquiring an additional 300 shares during the period. Geode Capital Management LLC grew its position in NewAmsterdam Pharma by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 102,395 shares of the company’s stock valued at $3,590,000 after buying an additional 437 shares during the period. The Manufacturers Life Insurance Company grew its position in NewAmsterdam Pharma by 5.3% during the second quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock valued at $197,000 after buying an additional 544 shares during the period. Farther Finance Advisors LLC grew its position in NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after buying an additional 708 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in NewAmsterdam Pharma by 26.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,510 shares of the company’s stock valued at $193,000 after buying an additional 1,156 shares during the period. 89.89% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Tuesday, April 21st. Truist Financial assumed coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, March 18th. They set a “buy” rating and a $57.00 target price for the company. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. Finally, Needham & Company LLC upped their price target on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $48.60.

NewAmsterdam Pharma Stock Performance

NAMS stock opened at $30.15 on Thursday. NewAmsterdam Pharma Company N.V. has a one year low of $17.63 and a one year high of $42.21. The company’s fifty day moving average price is $33.26 and its 200-day moving average price is $33.42. The company has a market capitalization of $3.52 billion, a PE ratio of -16.84 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The company had revenue of $3.04 million during the quarter. On average, research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current fiscal year.

Insider Transactions at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 65,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the sale, the chief accounting officer owned 24,353 shares of the company’s stock, valued at $869,158.57. This represents a 72.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 12.74% of the stock is currently owned by insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.